المؤلفون: Li Q; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China., Zhang K; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China., Yu Y; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China., Yu Z; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China., Xu J; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China., Shen W; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China., Zhang L; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China., Qu A; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China., Liang H; No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China.

المصدر: PloS one [PLoS One] 2024 Sep 25; Vol. 19 (9), pp. e0310889. Date of Electronic Publication: 2024 Sep 25 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/pharmacology , Antibodies, Bispecific*/immunology , Antigens, CD20*/immunology , Lymphoma, B-Cell*/immunology , Lymphoma, B-Cell*/therapy , Lymphoma, B-Cell*/drug therapy , Immunoglobulin Fab Fragments*/immunology , T-Lymphocytes*/immunology, Animals ; Mice ; Humans ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Lymphocyte Activation/immunology ; Lymphocyte Activation/drug effects ; Female

المؤلفون: Jeon SH; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., You G; ABL Bio Inc., Seongnam, Republic of Korea., Park J; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea., Chung Y; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea., Park K; ABL Bio Inc., Seongnam, Republic of Korea., Kim H; ABL Bio Inc., Seongnam, Republic of Korea., Jeon J; ABL Bio Inc., Seongnam, Republic of Korea., Kim Y; ABL Bio Inc., Seongnam, Republic of Korea., Son WC; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Jeong DS; Department of Medical Science, AMIST, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Shin EC; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea., Lee JY; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea., Han DH; Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea., Jung J; ABL Bio Inc., Seongnam, Republic of Korea., Park SH; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 13; Vol. 30 (18), pp. 4155-4166.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/pharmacology , Antibodies, Bispecific*/therapeutic use , CD8-Positive T-Lymphocytes*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Lymphocytes, Tumor-Infiltrating*/immunology , Lymphocytes, Tumor-Infiltrating*/drug effects , Tumor Necrosis Factor Receptor Superfamily, Member 9*/antagonists & inhibitors , Tumor Necrosis Factor Receptor Superfamily, Member 9*/immunology , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use, Animals ; Humans ; Mice ; Female ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Ovarian Neoplasms/immunology ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/immunology ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy ; Liver Neoplasms/immunology ; Liver Neoplasms/drug therapy ; Liver Neoplasms/pathology

المؤلفون: Lee K; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA., Chau JQ; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA., Suber YB; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA., Sternberg AR; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA., Pishko AM; Division of Hematology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., George LA; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.; Division of Hematology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA., Bhoj VG; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Doshi BS; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.; Division of Hematology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA., Samelson-Jones BJ; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.; Division of Hematology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA.

المصدر: Blood [Blood] 2024 Sep 12; Vol. 144 (11), pp. 1230-1235.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Factor IX*/genetics , Hemophilia B*/drug therapy , Hemophilia B*/blood , Hemophilia B*/genetics , Antibodies, Bispecific*/therapeutic use , Antibodies, Bispecific*/pharmacology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/pharmacology, Humans ; Blood Coagulation/drug effects

المؤلفون: Liu J; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China., Zhu J; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China; Jecho Laboratories, Inc., Frederick, MD 21704, USA. Electronic address: jianweiz@sjtu.edu.cn.

المصدر: International immunopharmacology [Int Immunopharmacol] 2024 Sep 10; Vol. 138, pp. 112609. Date of Electronic Publication: 2024 Jul 06.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/therapeutic use , Antibodies, Bispecific*/pharmacology , Neoplasms*/immunology , Neoplasms*/therapy , T-Lymphocytes*/immunology , Immunotherapy*/methods , Tumor Microenvironment*/immunology, Humans ; Animals ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/pharmacology

المؤلفون: Bayly-McCredie E; Epworth HealthCare, East Melbourne, VIC 3002, Australia., Treisman M; Epworth HealthCare, East Melbourne, VIC 3002, Australia., Fiorenza S; Epworth HealthCare, East Melbourne, VIC 3002, Australia.; Faculty of Medicine and Health, University of Sydney, Camperdown, NSW 2006, Australia.

المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Sep 09; Vol. 25 (17). Date of Electronic Publication: 2024 Sep 09.

نوع المنشور: Systematic Review; Journal Article; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/therapeutic use , Antibodies, Bispecific*/adverse effects, Humans ; Adult ; Lymphoma, Large B-Cell, Diffuse/immunology ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/therapy ; Clinical Trials as Topic ; Treatment Outcome ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects

المؤلفون: Lu C; Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China; Institute of Translational Medicine, Zhejiang University, Hangzhou, China., Zou L; Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China., Wang Q; Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China., Sun M; Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China., Shi T; Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China., Xu S; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China., Meng F; Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China., Du J; Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

المصدر: Biomolecules & biomedicine [Biomol Biomed] 2024 Sep 06; Vol. 24 (5), pp. 1424-1434. Date of Electronic Publication: 2024 Sep 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Association of Basic Medical Sciences of FBIH Country of Publication: Bosnia and Herzegovina NLM ID: 9918522188506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2831-090X (Electronic) Linking ISSN: 28310896 NLM ISO Abbreviation: Biomol Biomed Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/pharmacology , Antibodies, Bispecific*/therapeutic use , Antibodies, Bispecific*/immunology , T-Lymphocytes*/immunology , T-Lymphocytes*/metabolism , Proto-Oncogene Proteins p21(ras)*/genetics , Proto-Oncogene Proteins p21(ras)*/immunology , Proto-Oncogene Proteins p21(ras)*/antagonists & inhibitors , CD3 Complex*/immunology , CD3 Complex*/metabolism, Humans ; Animals ; Mice ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; HLA-A2 Antigen/immunology ; HLA-A2 Antigen/genetics ; Female

المؤلفون: Lu J; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Qiu H; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Wang Y; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Zhou X; Department of Hematology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, WuXi, China., Dai H; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Lu X; Department of Hematology, Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, Jiangsu, China., Yang X; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Gu B; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China.; Department of Hematology, Soochow Hopes Hematonosis Hospital, Suzhou, China., Hong M; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China., Miao M; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Lu R; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China., Wang J; Department of Hematology, Soochow Hopes Hematonosis Hospital, Suzhou, China., Wu Q; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Xue M; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Wang Y; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Deng A; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Shen Y; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Liu Y; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Dou X; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Lei Y; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China., Wu D; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China. drwudepei@163.com., Zhu Y; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. zhuyu@jsph.org.cn., Chen S; Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China. chensuning@sina.com.

المصدر: Journal of hematology & oncology [J Hematol Oncol] 2024 Sep 02; Vol. 17 (1), pp. 79. Date of Electronic Publication: 2024 Sep 02.

نوع المنشور: Clinical Trial, Phase II; Multicenter Study; Letter

بيانات الدورية: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/therapeutic use , Antibodies, Bispecific*/administration & dosage , Antibodies, Bispecific*/adverse effects , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Induction Chemotherapy*/methods, Humans ; Male ; Female ; Adult ; Middle Aged ; Young Adult ; Aged ; Adolescent ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Dexamethasone/adverse effects ; Remission Induction

المؤلفون: Wu X; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China., Lu S; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China., Zhang X; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China., Yang Z; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China., Sun A; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China., Wu D; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China., Zhou H; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China., Miao M; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

المصدر: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (17), pp. e70161.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/therapeutic use , Antibodies, Bispecific*/administration & dosage , Antibodies, Bispecific*/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/administration & dosage , Philadelphia Chromosome* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Male ; Adult ; Middle Aged ; Retrospective Studies ; Aged ; Treatment Outcome ; Young Adult ; Adolescent ; Tyrosine Kinase Inhibitors

المؤلفون: Cao Z; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia., Wichmann CW; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; School of Chemistry - Bio21 Institute, University of Melbourne, Melbourne, Australia., Burvenich IJG; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Osellame LD; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Guo N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., Rigopoulos A; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., O'Keefe GJ; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia., Scott FE; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Lorensuhewa N; Antengene Biologics Limited, Shanghai, China., Lynch KP; Antengene Biologics Limited, Shanghai, China., Scott AM; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia. Andrew.Scott@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Melbourne, Australia. Andrew.Scott@onjcri.org.au.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia. Andrew.Scott@onjcri.org.au.; Department of Medicine, University of Melbourne, Melbourne, Australia. Andrew.Scott@onjcri.org.au.

المصدر: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Sep; Vol. 51 (11), pp. 3202-3214. Date of Electronic Publication: 2024 May 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE

مواضيع طبية MeSH: Zirconium*/chemistry , B7-H1 Antigen*/metabolism , Antibodies, Bispecific*/pharmacokinetics , Antibodies, Bispecific*/chemistry , Antibodies, Bispecific*/immunology, Animals ; Mice ; Tissue Distribution ; Humans ; Cell Line, Tumor ; Radioisotopes/chemistry ; Deferoxamine/chemistry ; Deferoxamine/analogs & derivatives ; Positron-Emission Tomography ; Female ; Isotope Labeling ; Mice, Inbred BALB C ; Isothiocyanates

المؤلفون: Gibson A; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX. algibson2@mdanderson.org., Nunez C; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Robusto L; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston TX., Kammerer B; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Garcia M; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Roth M; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Sheth R; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Tewari P; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Hittle A; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Toepfer L; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Torres R; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Cuglievan B; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX., McCall D; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: Haematologica [Haematologica] 2024 Sep 01; Vol. 109 (9), pp. 3042-3047. Date of Electronic Publication: 2024 Sep 01.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Inotuzumab Ozogamicin* , Antibodies, Bispecific*/administration & dosage , Antibodies, Bispecific*/therapeutic use , Rituximab*/administration & dosage , Rituximab*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/therapy , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/pathology, Humans ; Child ; Male ; Female ; Adolescent ; Child, Preschool ; Recurrence ; Treatment Outcome ; Drug Resistance, Neoplasm